AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,260,000 shares, a drop of 25.4% from the December 15th total of 1,690,000 shares. Based on an average daily volume of 370,200 shares, the short-interest ratio is currently 3.4 days.

AlloVir Price Performance

NASDAQ:ALVR traded up $0.03 during trading hours on Wednesday, hitting $0.43. The company had a trading volume of 205,364 shares, compared to its average volume of 419,031. The company has a market capitalization of $49.91 million, a PE ratio of -0.49 and a beta of 0.65. The stock has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.69. AlloVir has a 52 week low of $0.38 and a 52 week high of $1.05.

AlloVir (NASDAQ:ALVR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10.

Institutional Trading of AlloVir

An institutional investor recently raised its position in AlloVir stock. Cubist Systematic Strategies LLC raised its position in shares of AlloVir, Inc. (NASDAQ:ALVR) by 152.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,816 shares of the company’s stock after buying an additional 30,072 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in AlloVir were worth $36,000 at the end of the most recent quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.